Last reviewed · How we verify

Corynebacterium granulosum P40 — Competitive Intelligence Brief

Corynebacterium granulosum P40 (Corynebacterium granulosum P40) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial immunotherapy / Cancer vaccine. Area: Oncology.

phase 3 Bacterial immunotherapy / Cancer vaccine Oncology Biologic Live · refreshed every 30 min

Target snapshot

Corynebacterium granulosum P40 (Corynebacterium granulosum P40) — Centro Oncologico de Excelencia. Corynebacterium granulosum P40 is a bacterial immunotherapeutic that stimulates anti-tumor immune responses through activation of innate and adaptive immunity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Corynebacterium granulosum P40 TARGET Corynebacterium granulosum P40 Centro Oncologico de Excelencia phase 3 Bacterial immunotherapy / Cancer vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial immunotherapy / Cancer vaccine class)

  1. Centro Oncologico de Excelencia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Corynebacterium granulosum P40 — Competitive Intelligence Brief. https://druglandscape.com/ci/corynebacterium-granulosum-p40. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: